id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-006131-t1ffey31	Chen, Jing	TRIPS-plus and access to medicines in China	2013-04-04		.txt	text/plain	3721	214	48	Ample evidence shows that Trade-related aspects of intellectual property rights (TRIPS)-plus provisions have seriously affected access to and availability of drugs in the developing countries. This article focuses on IP and the health implications of limited access to medicines in China, explores the TRIPS-plus arrangements in Chinese IP laws and regulations, and makes suggestions for China's negotiation strategy in resisting pressure from developed countries to tighten IP laws and regulations. TRIPS-plus refers to provisions that either exceed the requirements of TRIPS or eliminate flexibilities in implementing TRIPs. Some studies 2,3 forecast that TRIPS-plus would result in: delayed entry of generics into developing countries; significant price increases, and reduced access to medicines, thus posing serious threats to public health. 24 A higher standard of patent protection could result in losses for pharmaceutical industries in developing countries; China has lost public health advantage as compared with India -higher drug prices, lower drug availability, and underdeveloped domestic innovation capacity.	./cache/cord-006131-t1ffey31.txt	./txt/cord-006131-t1ffey31.txt